Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting
Authors:
- 1 December 2006
- journal article
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 19 (6) , 473-476
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Relationship between Cisplatin or Nedaplatin-Induced Nephrotoxicity and Renal AccumulationBiological and Pharmaceutical Bulletin, 2005
- Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian CarcinomaJNCI: Journal of the National Cancer Institute, 2004
- A phase II study of single-agent docetaxel in patients with metastatic esophageal cancerAnnals of Oncology, 2004
- Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancerBritish Journal of Cancer, 2002
- Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapyThe Journal of Thoracic and Cardiovascular Surgery, 2002
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal CancerJournal of Clinical Oncology, 1999
- Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassayCancer Chemotherapy and Pharmacology, 1991